JNJ,PFE -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Pfizer: Analysts’ Recommendations on October 22
    Market Realist2 hours ago

    Pfizer: Analysts’ Recommendations on October 22

    Analysts expect Pfizer’s (PFE) top line to increase ~2.9% to ~$13.5 billion during the third quarter. The company’s EPS is expected to increase to $0.75 in the third quarter—compared to $0.67 in the third quarter of 2017.

  • Pfizer: Analysts Expect Revenue Growth in Q3
    Market Realist4 hours ago

    Pfizer: Analysts Expect Revenue Growth in Q3

    As we discussed earlier, analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to revenues of $13.2 billion during the third quarter of 2017. The revenue growth is expected to be driven by innovative health products’ strong performance.

  • Pfizer’s Third-Quarter Earnings: Analysts’ Estimates
    Market Realist4 hours ago

    Pfizer’s Third-Quarter Earnings: Analysts’ Estimates

    Pfizer (PFE), one of the leading pharmaceutical companies, is scheduled to release its third-quarter earnings on October 30. For the third quarter, analysts expect Pfizer to report an EPS of $0.75 on revenues of $13.5 billion.

  • Novartis Reports Third-Quarter Revenue Growth
    Market Realist4 hours ago

    Novartis Reports Third-Quarter Revenue Growth

    Novartis (NVS), one of the leading healthcare companies, released its third-quarter earnings on October 18. Novartis surpassed Wall Street analysts’ estimates for EPS but missed estimates for revenues with reported EPS of $1.32 on revenues of ~$12.78 billion as compared to the estimated EPS of $1.31 on revenues of ~$13.02 billion during the third quarter of 2018.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet
    Zacks10 hours ago

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet

  • InvestorPlace10 hours ago

    Strong Earnings Enough Reason to Stay Long JNJ Stock

    Johnson & Johnson (NYSE:JNJ) has rallied nicely since the summer. JNJ stock touched a 15-month low in late May — but it’s rallied nicely. Johnson & Johnson stock touched an eight-month high last month before a modest pullback of late.

  • The Wall Street Journal3 days ago

    [$$] Pain Treatment Developer Centrexion Reveals IPO Plans

    Centrexion Therapeutics Corp., a pain treatment developer founded by the former leaders of Pfizer Inc. and Celgene Corp., on Friday disclosed plans to go public.

  • An Overview of JNJ’s Women’s Health & Wound Care Businesses
    Market Realist3 days ago

    An Overview of JNJ’s Women’s Health & Wound Care Businesses

    Johnson & Johnson’s (JNJ) women’s health business generated revenue of $269.0 million in the third quarter compared to $270.0 million in the third quarter of 2017. In the US and international markets in the quarter, the business generated revenues of $3.0 million and $266.0 million, respectively.

  • A Performance Overview of JNJ’s Beauty and OTC Businesses
    Market Realist3 days ago

    A Performance Overview of JNJ’s Beauty and OTC Businesses

    Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.

  • Investopedia3 days ago

    2 Dow Safety Stock for Volatile Market: Portfolio Manager

    As the Dow Jones Industrial Average (DJIA) index experiences a period of heightened volatility, healthcare stocks have proved relatively immune to the wider market swings. Healthcare players Pfizer Inc. ( PFE), UnitedHealth Group Inc. ( UNH) and Merck & Co., Inc. ( MRK), all members of the blue chip index, remain within short reach of their 52-week highs, while the DJIA has fallen 5.8% from its own as of Friday afternoon.

  • Motley Fool3 days ago

    What's Behind Johnson & Johnson's Q3 Earnings Success

    Here's why this healthcare giant is out-performing analyst expectations.

  • What $1,000 in Stocks Invested 10 Years Ago Would Be Worth Today
    GoBankingRates3 days ago

    What $1,000 in Stocks Invested 10 Years Ago Would Be Worth Today

    See how Apple stock and other big-name stocks have performed.

  • What’s Pfizer’s Current Valuation?
    Market Realist3 days ago

    What’s Pfizer’s Current Valuation?

    In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).

  • Pfizer’s Dividends and Earnings Quality
    Market Realist3 days ago

    Pfizer’s Dividends and Earnings Quality

    In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.

  • 10 S&P 500 Stocks to Buy for the Long Term
    Kiplinger3 days ago

    10 S&P 500 Stocks to Buy for the Long Term

    The last few days have been tough ones for too many investors in S&P 500 stocks. Though far from devastating, the existing backdrop of anxiety exacerbated the fear incited by the modest selloff. And traders still aren't sure what the foreseeable future holds. In simplest terms, it's just plain stressful. It's times like these when the "old school" approach of buy and hold -- meaning buy it and forget about it -- starts to sound compelling again. In other words, forget the day-to-day battles. Sit back and trust that time will do the heavy lifting for you. To that end, here's a rundown of 10 large-cap names that are well-suited for that precise approach. They're all S&P 500 stocks, and more than that, they're all names that don't require constant babysitting. You can count on them more or less being the same company a year from now, and even five years from now. In no particular order... SEE ALSO FROM KIPLINGER: 10 S&P 500 Stocks to Buy for Long-Term Outperformance

  • Pfizer Reported Revenue Growth in Global Markets
    Market Realist3 days ago

    Pfizer Reported Revenue Growth in Global Markets

    Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.

  • Reuters4 days ago

    Australian watchdog's appeal against Pfizer ruling dismissed by court

    The Australian Competition and Consumer Commission (ACCC) sought leave to appeal against a judgment by a Federal Court in May, when Pfizer was alleged to have abused its market power by offering big discounts and rebates on Lipitor to pharmacies. The drug stores were said to have bought large quantities of the drug and agreed to limit re-supply of competing generic atorvastatin products.

  • Reuters4 days ago

    Australian watchdog's appeal against Pfizer ruling dismissed by court

    Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor. The Australian Competition and Consumer Commission (ACCC) sought leave to appeal against a judgment by a Federal Court in May, when Pfizer was alleged to have abused its market power by offering big discounts and rebates on Lipitor to pharmacies.

  • Motley Fool4 days ago

    Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways?

    How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.

  • Investing.com4 days ago

    Intuitive Surgical Earnings miss, Revenue beats In Q3

    Investing.com - Intuitive Surgical (NASDAQ:ISRG) reported third quarter earnings that missed analyst's expectations on Thursday and revenue that topped forecasts.

  • Pfizer’s Growth Rate and Estimates
    Market Realist4 days ago

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

  • Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch
    Zacks4 days ago

    Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch

    Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.

  • What Are Pfizer’s Revenue Drivers?
    Market Realist4 days ago

    What Are Pfizer’s Revenue Drivers?

    Pfizer (PFE) reported revenues of $13.5 billion during the second quarter—4% revenue growth YoY compared to $12.9 million during the second quarter of 2017. The revenues are expected to increase 2.8% to $13.5 billion during the third quarter.

  • Novartis Missed Revenue Estimates in Q3 2018
    Market Realist4 days ago

    Novartis Missed Revenue Estimates in Q3 2018

    Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.